{"id":"anti-pseudomonal-cephalosporin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These are beta-lactam antibiotics that target gram-negative bacteria, particularly Pseudomonas aeruginosa, which are resistant to earlier-generation cephalosporins. They penetrate the outer membrane of gram-negative organisms and covalently bind to penicillin-binding proteins, preventing cross-linking of peptidoglycan and causing bactericidal cell lysis.","oneSentence":"Anti-pseudomonal cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall disruption and bacterial death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:17:09.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream)"},{"name":"Gram-negative aerobic bacterial infections in hospitalized patients"}]},"trialDetails":[{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT05094154","phase":"PHASE4","title":"Effect of Antibiotic Choice On ReNal Outcomes (ACORN)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-11-10","conditions":"Sepsis, AKI, Neurotoxicity","enrollment":2634}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"anti-pseudomonal cephalosporin","genericName":"anti-pseudomonal cephalosporin","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-pseudomonal cephalosporins inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall disruption and bacterial death. Used for Pseudomonas aeruginosa infections (respiratory, urinary, wound, bloodstream), Gram-negative aerobic bacterial infections in hospitalized patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}